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dollars to support clinical research cannot be expected.
They also noted that traditional financial support of
clinical research in academic medical centers through
cross-subsidization (ie, the use of clinical revenue) is
threatened by competitive pressures from managed
care. This, in addition to the loss of patients, denial of
reimbursement and competition with managed care
organizations, have placed academic medical centers
under unprecedented pressure. Despite these pressures,
unsponsored clinical research, defined as that not
directly grant supported, continues at many academic
medical centers. However, the report continues, part-
nerships between public and private entities serve to
maximize productivity.
Weissman and colleagues2 recently looked at the role
that market forces play on unsponsored research in aca-
demic medical centers. He found that approximately
75% of medical school faculty members were involved
in some unsponsored research effort. The proportion of
direct cost budgets supported by institutional money
was smaller in those medical schools in more competi-
tive markets, especially among the most research-inten-
sive institutions. This study also noted, however, that
much of the unsponsored research led to publications,
grants, and patent applications. They concluded that, as
the market becomes more competitive, faculty members
may have to work extra hours to do what may be cov-
ered by “protected time” in less competitive markets.
Because academic output is essential to promotion,
these faculty members may have to do “whatever it
takes” to achieve their career goals.
With the stock market achieving unprecedented lev-
els of growth and many companies setting records for
earnings over the past few years, the corporate world is
where the money resides; and there seems to be a
renewed emphasis on the part of many of these compa-
nies to fund the research of investigators outside of the
company. Often these funds are more readily available
T he first question often asked by young surgicalinvestigators is “Why partner with industry at all?”
Most young investigators are under the impression that
only the “hard money” (ie, National Institutes of Health
[NIH]) money, counts when one is seeking academic
advancement. In reality this is not the case, but it is the
easiest source of funding to track, and the indirect costs
that flow to the institution usually are significantly
higher when the government is the granting agency.
Thus government money (and by this we usually are
referring to NIH money) is usually preferred by acade-
mic institutions. However, we all must recognize that
government support for research is extremely competi-
tive and is likely to become less available in the coming
years, especially for “part-time” investigators like sur-
geons. Despite NIH talk of the desire to fund transla-
tional research, money for these types of projects is
extremely tight, and the key for successful funding
remains hypothesis-driven, mechanistic work. Trans-
lational research projects often fall short on mechanis-
tic specific aims, the investigators preferring instead to
look at outcomes of various interventions.
In a recent report from the American Medical
Association Council of Scientific Affairs,1 which inves-
tigated clinical research, there were several conclusions
that must be scrutinized closely by all academic institu-
tions. The Council concluded that future NIH budgets
likely will remain constant, at best, and thus additional
Academic surgeons should be aware of the tremendous potential that exists
to partner with private companies on projects relating either to basic or clin-
ical research. This is particularly timely now because many of these compa-
nies are experiencing unprecedented growth and market valuation. The
development of these relationships requires knowing who to deal with as
well as how to negotiate. Most academic medical centers have individuals
who have expertise in developing sponsored research agreements, and young
investigators should take advantage of this expertise. (J Thorac Cardiovasc
Surg 2000;119:S29-32)
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THE ACADEMIC SURGEON AND INDUSTRY
to fund clinical research questions than are funds from
NIH. Most companies are interested in specific target-
ed research questions and are looking to deal with
investigators who possess expertise in the company’s
area of interest. These monies may be more readily
obtainable by junior investigators, especially when
there is the backing of a well-established investigator
as the sponsor.
Competing interests of academic surgeons and
industry
It is safe to say that in the past, and not necessarily the
distant past, financial relationships between academic
institutions and industry to support research were con-
sidered taboo and perhaps even “antiacademic,” espe-
cially by the more elite institutions. Clearly, there has
been a paradigm shift because now these relationships
are sought by academicians who are eager to partner
with the deep pockets of an industry partner. Both par-
ties in the relationship bring something significant to the
table; I will deal with the academic surgeon as the rep-
resentative of the academic institutions. Most of the
relationships between universities and industry are
forged by individual investigators who are looking at
specific problems that interest a particular company. In
beginning a relationship with a for-profit company, the
academic surgeon brings a desire to advance knowledge
and improve patient care as global objectives and a need
to aid in his or her own academic promotion and repu-
tation among colleagues as individual objectives. The
company’s overall primary objective is to maintain or
increase profits, with a secondary objective to improve
patient care. The profit motive is always in the back-
ground and rightly so, but this does not necessarily have
to impede a research effort. The academic investigator
must understand that any decisions made by the compa-
ny (and this includes decisions relating to who and what
to fund) have to be made with the bottom line kept in
mind. Most companies establish priorities that relate to
areas where money is to be spent, recognizing the
potential impact of these dollars in the long run.
Where do I find an industry partner?
A common concern expressed by many academic sur-
geons deals with how one identifies an industry partner
and how one develops the relationship. We have found
that scientific meetings often serve as an ideal forum at
which representatives of industry and academia can
come together. Some of these meetings actually may be
sponsored by corporations that are interested in the
exchange of new ideas. Other meetings that are direct-
ed toward specific topics also tend to bring out industry
representative who may be involved in similar work.
Whereas in the past, it was distinctly uncommon to see
scientists from companies engaged in similar work at
meetings such as these, now they almost outnumber
those investigators from academic institutions. One
such meeting is that dealing with gene therapy of can-
cer that is held in November of each year in San Diego,
California, and is sponsored by the Kimmel Cancer
Center at the Scripps Medical Institutions. Young inves-
tigators can mingle with representative from various
companies at meetings such as this, networking to fos-
ter collaborative efforts. One cannot overestimate the
importance of this type of networking for a young
investigator. It has been the policy of our laboratory to
send at least 4 of our people every year and always to
have several abstracts on the program for presentation.
Other potential sites for meeting corporate representa-
tives include the larger meetings at which multiple
exhibitors are present, such as the American College of
Surgeons or the American College of Chest Physicians.
Younger investigators should be aware of more senior
investigators at their home institutions who may have
contacts within certain companies.
What you as an academic surgeon bring to the
table
There is a symbiotic relationship that exists between
industry and academic institutions. Seemingly, they
need us as much as we need them. What does the aca-
demic surgeon bring to a relationship with a private
company? First, and foremost, the academic surgeon
offers the company credibility and independent confir-
mation of research findings that the company may have
obtained. Not to be underestimated is the manpower
that the academic surgeon brings because many com-
panies, especially smaller ones, do not have the neces-
sary capacity to conduct all necessary preclinical stud-
ies or clinical studies. Second, and perhaps as
important, the academic surgeon has control over
patients who are potentially available for clinical stud-
ies and patient material such as tumor tissue. Finally,
companies are looking for expertise outside of what
they possess, and academic surgeons admirably fill this
role. The relationship between the academic surgeon
and a company usually is easier to consummate if the
investigator already has some expertise in the area of
the company’s interest. Often someone from a given
company will contact an individual investigator either
after hearing work presented at a meeting or seeing a
published article. This has especially been the case in
the field of gene therapy; many start-up companies
have benefitted from investigations conducted at an
academic institution or when these newer companies
have gone looking for additional expertise.
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Resources available at academic institutions to
foster industry collaborations
Before beginning negotiations with a private company
that wishes to support a research effort, it behooves the
academic surgeon to seek out available resources with-
in one’s own institution. What is available varies from
institution to institution, but all institutions have some
capability to deal with private industry support for
research, so-called sponsored research agreements
(SRAs). Many institutions may have an Office of
Technology Transfer that is perhaps more involved with
the profit potential of new technology developed by fac-
ulty members, but this type of work may be the genesis
of a relationship with a private company or the begin-
ning of a start-up company (Fig 1). There may exist an
administrator who deals specifically with industry rela-
tionships, such as the situation we have at the University
of Pennsylvania in which we have a Senior Vice-
President for Venture and Industry Relationships. The
particular individual who holds this position has a
Master of Business Administration degree and is a cer-
tified public accountant. Likely there are other faculty
members at a given institution who have successfully
established collaborations with industry, and these indi-
viduals should be able to provide support and expertise.
SRAs
Our own experience in initiating and developing an
SRA is illustrative and brings up a number of points. It
is particularly important to work through the Office of
Technology Transfer because that office has the exper-
tise to negotiate these arrangements much more so than
any individual investigator. Because as academic sur-
geons we act as representatives of the university, the
university must be a party to any and all agreements,
and thus the university assumes some liability. Because
of this the university requires certain clauses to be
included in any agreement with an outside party. These
items vary from university to university, and some uni-
versities may even let investigators negotiate on their
own, with the university not being included as a party.
Mostly the university wants in on these arrangements
because of the indirect costs that go to the university as
part of any SRA, and most SRAs require the signature
of an appropriate university official. Any given SRA
may take up to 1 year to successfully complete the
agreement between the university and the private com-
pany. It goes without saying that the funds from an
SRA should be used solely for the purpose intended.
We have certain needs and interests as academic sur-
geons that need to be protected. As academic
researchers, our currency is publication. From the
standpoint of advancement professionally and promo-
tion academically, timely publication of significant
research findings is of paramount importance. This dif-
fers significantly from the mission of a private, for-
profit company for which profit is always the underly-
ing motive and publication may be a significantly
lesser concern, especially if their patent position is
weak on a given technology. It is naive to think that any
company is engaged in research for any sort of altruis-
tic motive. Helping mankind most certainly is a part of
the thinking of most biomedical companies, but they
prefer to do this while making money. Academic
researchers cannot be in the position of having to agree
to a “gag clause” that prevents the unauthorized release
of any findings. It is reasonable that a company has the
right to review an article before it is published; it is not
reasonable for a company to control what a researcher
can publish. It is because of these concerns that an
Office of Technology Transfer is so important; those
individuals engaged in the development of these agree-
ment on a daily basis serve to protect individual inves-
tigators and the university. This office also must be
involved in agreements between the private company,
the university, and the individual investigators with
regard to the intellectual property rights to new tech-
nology that is developed during the course of an SRA.
Finally, institutional overhead often is a sticking point
because most companies do not want to pay the same
rate negotiated by a given university with the NIH.
Most seek to pay significantly less in indirect costs to
the university, but many universities take a hard line
with these negotiations.
In any SRA, we as academic surgeons must not lose
sight of the primary goals of protecting the patient’s
health, teaching and advancing knowledge despite
pressure to seek funds from what were once considered
nontraditional sources. Soliciting research funds from
Fig 1. Organization of a typical Office of Technology Transfer.
University of Pennsylvania
 Center for Technology Transfer
— Managing Director: Louis P. Berneman
— Staff:
 Dir. Operations and Licensing
 Dir. Licensing Life Sciences
 Dir. Intellectual Property
 Dir. Licensing Physical Services
 Dir. Start-up Business Development
made both to one’s colleagues and peers and to subjects
recruited for the study. This disclosure must be a part of
any published work and should be made at such time as
the work is presented at a research meeting. All con-
flicts of interest must be fully disclosed. Without such
disclosure, our intellectual honesty is subject to ques-
tions and all credibility ultimately may be lost. One
cannot overestimate the importance of complete disclo-
sure in an era when we are encouraging and seeing
more industry-sponsored research. In my opinion, and
that of many others, the safest course for the academic
investigator is to have no financial interest in the com-
pany that is supporting the research.
Conclusions
All academic surgeons engaged in research endeav-
ors should be aware of the potential and desire on the
part of private industry to fund either basic (usually
translational) or clinical research. Often this type of
support leads to the preliminary data necessary to be
able to compete for NIH funding, publication, and
patent applications. There should be no stigma attached
to industry funding as long as there is full and complete
disclosure of the relationship between the investigator
and the company. Partnerships between academic sur-
geons and industry can lead to rapid advancement in
knowledge and improvements in therapy and thus
should be encouraged. It is incumbent on young sur-
geons to seek out expertise within their own institutions
to aid them in developing these relationships.
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private companies must always be secondary to patient
safety and integrity of research. Of course, it remains
the responsibility of the investigator to assure the
integrity and honesty of the research.
The NIH and industry
The NIH has recognized the role that private industry
may play in fostering scientific initiative and advance-
ment and has developed 2 programs of which academ-
ic surgeons should be aware. The first, the Small
Business Technology Transfer Program is designed to
stimulate and foster scientific innovation through coop-
erative research carried out between small business
concerns and research institutions. A second aim of this
program is to increase private sector commercialization
of innovations derived from federal research and devel-
opment, which obviously includes research funded by
government funds. The second program, the Small
Business Innovation Research Program encourages
small businesses to explore technologic potential and
provides incentive to profit from commercialization.
There is a specific percent of federal research and
development funds reserved for small business, mainly
to support the critical start-up and development stages.
Academic surgeons partnered with industry may bene-
fit from both of these programs. More specific infor-
mation regarding these innovative government pro-
grams may be found on the NIH web site
(www.nih.gov).
Implications of industry-sponsored research
As academic surgeons, our integrity, character, and
intellectual honesty are of paramount importance.
Despite the importance of the profit motive to private
industry, an academic researcher must not be influ-
enced by a similar profit motive. A surgeon who per-
sonally benefits financially while conducting a research
study is walking an ethical tightrope, especially if there
is not full and complete disclosure. Recently, evidence
has emerged that research outcomes can be influenced
by those who fund the research.3 This particular study
involved calcium-channel blockers. Full disclosure
must be made if the investigator has a financial interest
in the outcome of a project. This disclosure should be
